Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine.

By J. Treanor, J. Campbell, K. Zangwill, T. Rowe, M. Wolff. New England Journal of Medicine, 2006

720 citations recorded by the source corpus.

Subfields: Epidemiology, Pulmonary and Respiratory Medicine

View Paper: https://www.semanticscholar.org/paper/a1ec927991acccd0b517cefed23ac36e06b8f1dc

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Epidemiology

1. J. Peiris
2. M. D. de Jong
3. Yi Guan

Citations in the corpus

• Technology transfer of an oil-in-water vaccine-adjuvant for strengthening pandemic influenza preparedness in Indonesia. (2013, background): “For split and subunit H5N1 influenza vaccines, 90 g (haemagglutinin content) dose is required to elicit an dequate immune response that meets registration criteria [5].”
• Avian Influenza Virus (H5N1): a Threat to Human Health (2007, background): “H5N1 subunit vaccines adjuvanted with aluminum phosphate modestly increased immunogenicity but not to levels that would make large-scale H5N1 vaccine production a feasible proposition (13, 208, 209, 233).”
• Human Immunodeficiency Virus Type 1 Elite Neutralizers: Individuals with Broad and Potent Neutralizing Activity Identified by Using a High-Throughput Neutralization Assay together with an Analytical Selection Algorithm (2009, neutral): “Screened on panel 4 Site 1 Rwanda (100) 49 (49) 51 (51) 100 A Site 2 Uganda (58) 18.”